Loading
Gold Glyconanoparticles / Nanovaccines / Metal Nanoparticles · Journal article
Emerging Microbes & Infections · July 24, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical and translational study investigating gold nanoparticle-based vaccines carrying Listeria monocytogenes peptides (GAPDH and LLO) in pregnant mice and isolated human dendritic cells. The authors report that nanovaccines prevented neonatal listeriosis and comorbidities better than prenatal or postnatal ampicillin in mice, and that GAPDH nanovaccines showed immunogenic capacity in human blood cells; however, no clinical efficacy data, controlled human trials, or quantified effect sizes are provided.
Preclinical experimental study in pregnant mice; translational in vitro dendritic cell assays in human blood cells.. Pregnant female C57BL/6, CBA/J, and BALB/c mice representing resistant, intermediate, and highly susceptible strains to Listeria monocytogenes; selected patients with listeriosis under treatment or not at two Spanish hospitals (Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla…. Intervention: Gold glyconanoparticles coupled to Listeria monocytogenes GAPDH (GAPDH 1-22) or listeriolysin O (LLO 91-99) peptides administered to pregnant mice; nanovaccines evaluated for immunomodulation capacity in isolated human monocyte-derived den…. Compared with: Prenatal or postnatal ampicillin treatment in pregnant mice; patients with listeriosis receiving antibiotic treatment or not.. Spain (Santander and Gipuzkoa); mice obtained from Charles River..
Nanovaccines prepared with gold nanoparticles and LLO or GAPDH peptides prevented neonatal listeriosis in pregnant female mice better than pre- or postnatal ampicillin treatment. GAPDH nanovaccines demonstrated strong and specific immunogenic capacity as putative immunotherapies when evaluated in blood cells from patients with listeriosis. Ampicillin remains the main antimicrobial therapy for adult and neonatal listeriosis; prophylactic treatments are currently lacking.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is exploratory and does not yet support clinical application. Clinicians should await human efficacy trials before considering nanovaccines as an alternative to ampicillin for listeriosis prevention or treatment. The in vitro immunomodulation data suggest a potential mechanism but require in vivo confirmation in human subjects.
Early-phase preclinical and translational work comparing nanovaccines to antibiotics in mouse models of neonatal listeriosis and in vitro dendritic cell immunomodulation; lacks clinical trial data and human efficacy endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This work is exploratory and does not yet support clinical application. Clinicians should await human efficacy trials before considering nanovaccines as an alternative to ampicillin for listeriosis prevention or treatment. The in vitro immunomodulation data suggest a potential mechanism but require in vivo confirmation in human subjects.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Although the main antimicrobial therapy for adult and neonatal listeriosis is ampicillin, prophylactic treatments are currently lacking. We compared the efficiency of nanovaccines with prenatal or postnatal ampicillin treatments in pregnant female mice during the development of neonatal listeriosis. Nanovaccines prepared with gold nanoparticles and listeriolysin O (LLO) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) peptides and inoculated into pregnant females, prevented neonatal listeriosis and the appearance of comorbidities, better than pre or postnatal ampicillin treatment. Evaluation of the ability of nanovaccines as immunomodulators of blood cells in patients with listeriosis, revealed the strong and specific immunogenic capacity of the use of GAPDH nanovaccines as putative immunotherapies in listeriosis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.